POSB160 Cost-Effectiveness of Dapagliflozin Compared to DPP-4 Inhibitors as Combination Therapy with Metformin in the Treatment of Type 2 Diabetes Mellitus without Established Cardiovascular Disease in Colombia

Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.433
https://www.valueinhealthjournal.com/article/S1098-3015(21)02228-2/fulltext
Title : POSB160 Cost-Effectiveness of Dapagliflozin Compared to DPP-4 Inhibitors as Combination Therapy with Metformin in the Treatment of Type 2 Diabetes Mellitus without Established Cardiovascular Disease in Colombia
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02228-2&doi=10.1016/j.jval.2021.11.433
First page :
Section Title :
Open access? : No
Section Order : 11210
Categories :
Tags :
Regions :
ViH Article Tags :